The non-responsiveness of cancer cell lines and organoids with other mutations but lacking PI3K and MAPK pathway alterations might suggest that the treatment combination will also not affect normal (isolated from healthy mucosa) organoids lacking any mutations, thereby leading to the assumption of low damage to the healthy tissue of the targeted organ. This evidence concerns the gene PIK3CG and cancer.